Health Care · Pharmaceutical Preparations

ANIP ANI PHARMACEUTICALS INC SEC Filings & Insider Trading Activity 2026

company
CIK 1023024142 filings
Russell 2000

ANIP at a glance

ANI PHARMACEUTICALS INC (ANIP, SEC CIK 1023024) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ANI PHARMACEUTICALS INC (ANIP) reported revenue of $883.4 million (up 43.8% from FY2024) and net income of $78.3 million. Diluted EPS was $3.32.
  • As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding ANI PHARMACEUTICALS INC (ANIP) shares worth $645.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Lalwani Nikhil on November 18, 2026 of 4,082 shares at $71.16 per share.
  • In the last 90 days, ANIP insiders reported 0 open-market purchases ($0) and 12 open-market sales ($2.4M) on Form 4, a net sale of $2.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$883.4M
+43.8% vs prior year
Insiders · 90 days
0 buys · 12 sells
Net −$2.4M
13F holders
31 funds
$645.7M · −3 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: developing, manufacturing, commercializing therapeutics via Rare Disease, Generics, and Brands segments
  • Acquired Alimera Sciences on September 16, 2024, adding ILUVIEN® and YUTIQ® products
  • Strategic expansion into ophthalmic specialty products through acquisition
  • Acquisition introduces new product lines, diversifying portfolio beyond prior scope

Risk Factors

  • Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products
  • Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions
  • Operational/supply chain risk: Reliance on single-source third-party contract manufacturers for Cortrophin Gel and ILUVIEN, risking commercialization delays if noncompliant or unavailable
  • Competitive risk: Dependence on Cortrophin Gel, competing with major pharma companies and generics that may have fewer side effects and higher physician acceptance
  • Financial/structural risk: 2024 Credit Agreement contains restrictive financial covenants, with potential for accelerated debt repayment and termination if breached

Management Discussion & Analysis

  • Total revenue details not provided for FY 2024; Alimera acquisition adds ILUVIEN® and YUTIQ® franchises
  • No segment-specific revenue or profit data disclosed
  • Sale of Oakville facility for $14.2 million completed in March 2024; no other cash flow or capital allocation details given
  • Management highlights growth via ILUVIEN label expansion and Alimera acquisition; no formal guidance or risk outlook stated

AI summary of the ANIP 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New acquisition risk: Egetis offer requires 90% tender acceptance and regulatory clearances, including HSR and foreign-investment approvals
  • Most material update: Offer failure could leave significant transaction costs and depress ANI’s share price
  • Regulatory risk: Swedish takeover conditions include government approvals and potential restrictions or divestitures
  • Financial risk: $676.0 million 364-day bridge facility may require substantial cash servicing and refinancing
  • Currency risk: SEK 5.6 billion purchase consideration remains unhedged against Swedish krona appreciation

Management Discussion & Analysis

  • Q3 revenue $290.8M, up 27.6% YoY from $227.8M
  • Operating margin 18.0% vs 16.1%; net margin 12.0% vs 11.8%
  • Best performer: Cortrophin Gel revenue $138.7M, up 36.1%; worst: Brands revenue $10.0M, down 6.5%
  • Cash $420.8M vs $285.6M at December 31, 2025; nine-month operating cash flow $198.8M vs $154.9M
  • Q3 share repurchases $7.5M; management expects resources sufficient for obligations over next 12 months, with financing needs possible if assumptions change

AI summary of the ANIP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated investor presentation published November 16, 2026
  • Materials intended for investor and analyst meetings

Item EX-99.1: Item EX-99.1

  • 2026 guidance: revenue $1.085B-$1.125B, adjusted EBITDA $290M-$300M, adjusted EPS $9.37-$9.71
  • Rare Disease expected to exceed 50% of 2026 revenue, accelerating ANI’s shift away from generics
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary contained in Exhibit 99.1 press release

Item 7.01: Regulation FD Disclosure

  • Investor presentation covers third-quarter 2026 results
  • Presentation addresses proposed Egetis Therapeutics acquisition

Item EX-99.2: Item EX-99.2

  • Q3 2026 revenue $290.8M, up 28% YoY, with adjusted non-GAAP EBITDA $83.3M, up 40%
  • Rare Disease revenue $138.7M, up 36% YoY, driven by Cortrophin Gel momentum and gout expansion

Item EX-99.1: Item EX-99.1

  • Q3 revenue $290.8M, up 27.6%, with adjusted EBITDA $83.3M, up 39.8%, signaling strong operating momentum
  • Cortrophin Gel revenue $138.7M, up 36.1%, but specialty-pharmacy capacity constrained conversion from demand into treated patients
Filed Nov 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • ANI is preparing a voluntary cash offer for Egetis Therapeutics at SEK 11.25 per share
  • Proposed consideration also includes SEK 65,750,817 per convertible and SEK 6.99 per warrant

Item EX-99.2: Item EX-99.2

  • Recommended acquisition of Egetis for approximately SEK 5.6B, or $560M, financed with cash on hand and new JPMorgan debt
  • Net enterprise value approximately $434M after Egetis’ planned $190.0M PRV sale and related earn-out obligations

Item EX-99.3: Item EX-99.3

  • Recommended cash acquisition of Egetis for approximately SEK 5,304 million, expanding ANI’s rare-disease platform with EMCITATE
  • Offer price SEK 11.25 per share, premiums of 12.6% to last close, 27.0% to 60-day average and 48.0% to 180-day average

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 points to Item 1.01 for the underlying borrowing or financial obligation details
  • Investor impact depends on the referenced agreement’s amount, pricing, maturity, and purpose

Item EX-99.4: Item EX-99.4

  • Egetis board unanimously recommends ANI’s SEK 5,304 million cash offer, supporting ANIP’s acquisition of a commercial-stage rare-disease platform
  • Consideration: SEK 11.25 per share, SEK 65,750,817 for the EUR 3 million convertible, and SEK 6.99 per warrant

Item 1.01: Entry into a Material Definitive Agreement

  • $676 million 364-day senior bridge facility supporting ANI’s proposed cash offer for Egetis Therapeutics
  • Facility also earmarked to refinance ANI’s existing term loans and certain Egetis indebtedness

Item 8.01: Other Events

  • Recommended cash offer for Egetis: SEK 5.6B, approximately $559.9M total consideration
  • Consideration: SEK 11.25 per share, SEK 65,750,817 for the Convertible, and SEK 6.99 per Warrant

AI summaries of ANIP 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ANIP

Don't miss the next ANIP filing

  • Alerts as it files. A push when ANIP files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ANIP, by share count.
  • Ask anything. An AI agent that reads every ANIP filing and answers with sources.

ANIP alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Lalwani NikhilSellNov 18, 2026$71.16
Lalwani NikhilSellNov 16, 2026$71.40
Cook MeredithSellNov 13, 2026$70.80
CAREY STEPHEN P.SellOct 29, 2026$72.87
Lalwani NikhilSellOct 15, 2026$71.89
Cook MeredithSellOct 13, 2026$73.59
CAREY STEPHEN P.SellSep 29, 2026$73.00
Lalwani NikhilSellSep 15, 2026$71.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$614.4M$883.4M
Operating Income-$584K$111.1M
Net Income$18.8M-$18.5M$78.3M
Op. Margin-0.1%12.6%
Net Margin--3.0%8.9%
Balance Sheet
Total Assets$904.4M$1.3B$1.4B
Equity-$403.7M$540.7M
ROE--4.6%14.5%
Per Share
EPS$0.85$-1.04$3.32
Cash Flow
Operating CF-$64.0M$185.2M
CapEx$8.9M$16.2M$13.8M

Source: XBRL data in ANI PHARMACEUTICALS INC (ANIP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ANIP share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ANIP shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202631$645.7M
Q2 202634$735.1M
Q1 202632$663.3M
Q4 202531$688.2M
Q3 202530$772.5M
Q2 202529$590.4M
Q1 202528$498.0M
Q4 202422$318.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 237 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ANIP filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
8-KNov 16, 2026Analysis-
4Nov 13, 2026--
8-KNov 5, 2026Analysis-
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 30, 2026--
4Oct 16, 2026--
4Oct 13, 2026--
4Sep 30, 2026--
4Sep 16, 2026--
4Sep 14, 2026--
4Sep 14, 2026--
4Sep 1, 2026--
4Aug 27, 2026--
4Aug 26, 2026--
8-KAug 24, 2026Analysis-
4Aug 13, 2026--
4Aug 11, 2026--
8-KAug 7, 2026Analysis-
10-QAug 7, 2026Analysis
4Jul 30, 2026--
4Jul 21, 2026--
4Jul 14, 2026--
4Jul 6, 2026--

Related Health Care companies

All Health Care →

ANIP SEC filings: frequently asked questions

Are ANIP insiders buying or selling?

In the last 90 days, ANI PHARMACEUTICALS INC (ANIP) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $2.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ANIP stock?

As of September 30, 2026, the largest ANI PHARMACEUTICALS INC (ANIP) holders among the 13F filers tracked by SignalX were BlackRock ($229.3 million), State Street Corp ($69.1 million), Vanguard Capital Management LLC ($65.7 million), Dimensional Fund Advisors ($52.9 million), Vanguard Portfolio Management LLC ($30.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ANIP's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ANI PHARMACEUTICALS INC (ANIP) reported revenue of $883.4 million (up 43.8% from FY2024) and net income of $78.3 million. Diluted EPS was $3.32. The figures come from the XBRL data in the 10-K.

What are the main risks in ANIP's latest 10-K?

In the 10-K filed February 27, 2026, ANI PHARMACEUTICALS INC (ANIP) flagged: Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products. Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions. (AI summary of the Risk Factors section.)

What did ANIP report in its latest 8-K?

ANI PHARMACEUTICALS INC (ANIP) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Updated investor presentation published November 16, 2026.

What are the latest ANIP SEC filings?

ANI PHARMACEUTICALS INC (ANIP) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 18, 2026.

What is ANIP's SEC CIK number?

ANI PHARMACEUTICALS INC (ANIP)'s SEC Central Index Key (CIK) is 1023024. EDGAR lists every ANIP filing under that number.

Ask anything about ANIP

The research agent reads ANIP's filings, financials, insider trades and 13F holders, then answers with sources.